AVPR2 and autosomal dominant polycystic kidney disease: Vasopressin V2 receptor antagonists were shown to slow cystic development and preserve kidney function in rodent models orthologous to human ARPKD, autosomal dominant polycystic kidney disease (ADPKD), and nephronophthisis, supporting the role of vasopressin in PKD pathogenesis [19–22].